Influence of N-acetylcysteine Maintenance on the Pharmacodynamic Effects of Oral Ethanol

Overview

Journal Pharmacol Biochem Behav

Publisher Elsevier

Specialties Biochemistry
Pharmacology
Psychology
Social Sciences

Date 2020 Sep 6

PMID 32891709

Citations 5

Authors

William W Stoops

Justin C Strickland

Lon R Hays

Abner O Rayapati

Joshua A Lile

Craig R Rush

Affiliations

Soon will be listed here.

Abstract

Rationale: Glutamate systems play an important role in the abuse related effects of alcohol. n-Acetylcysteine, a drug that promotes glutamate homeostasis, attenuates a range of alcohol effects in preclinical models.

Objectives: This human laboratory study determined the influence of n-acetylcysteine maintenance on alcohol self-administration using a model predictive of treatment effectiveness, along with the subjective, performance and physiological effects of alcohol. We hypothesized that n-acetylcysteine would attenuate alcohol self-administration, as well as positive subjective effects of alcohol.

Methods: Nine subjects with alcohol use disorder completed this within-subjects study. Subjects were maintained on placebo, 1.2 and 2.4 g n-acetylcysteine in random order on an outpatient basis. After five days of maintenance on the target dose, subjects completed overnight inpatient experimental sessions in which the pharmacodynamic effects of alcohol were determined.

Results: Alcohol produced prototypic effects (e.g., increased breath alcohol concentration, increased ratings of Feel Drink). n-Acetylcysteine did not alter the effects of alcohol.

Conclusions: These results indicate that although n-acetylcysteine can safely be combined with alcohol, it does not attenuate the abuse related effects of alcohol and is unlikely to be an effective standalone alcohol use disorder treatment. However, considering study limitations, future work is needed to further understand whether and how n-acetylcysteine might be used as a treatment for alcohol use disorder (e.g., in combination with a behavioral treatment or another pharmacological agent).

Citing Articles

N-acetylcysteine does not alter neurometabolite levels in non-treatment seeking adolescents who use alcohol heavily: A preliminary randomized clinical trial.

Kirkland A, Browning B, Green R, Liu H, Maralit A, Ferguson P Neuropsychopharmacology. 2023; 48(8):1184-1193.

PMID: 36878996 PMC: 10267108. DOI: 10.1038/s41386-023-01553-z.

Current Therapeutic Options and Potential of Mesenchymal Stem Cell Therapy for Alcoholic Liver Disease.

Han J, Lee C, Hur J, Jung Y Cells. 2023; 12(1).

PMID: 36611816 PMC: 9818513. DOI: 10.3390/cells12010022.

Logical fallacies and misinterpretations that hinder progress in translational addiction neuroscience.

Strickland J, Stoops W, Banks M, Gipson C J Exp Anal Behav. 2022; 117(3):384-403.

PMID: 35362559 PMC: 9090969. DOI: 10.1002/jeab.757.

Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.

Burnette E, Nieto S, Grodin E, Meredith L, Hurley B, Miotto K Drugs. 2022; 82(3):251-274.

PMID: 35133639 PMC: 8888464. DOI: 10.1007/s40265-021-01670-3.

Evaluating N-acetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers.

McClure E, Wahlquist A, Tomko R, Baker N, Carpenter M, Bradley E Drug Alcohol Depend. 2021; 225:108815.

PMID: 34171822 PMC: 8282766. DOI: 10.1016/j.drugalcdep.2021.108815.

References

Leelarungrayub D, Khansuwan R, Pothongsunun P, Klaphajone J . N-acetylcysteine supplementation controls total antioxidant capacity, creatine kinase, lactate, and tumor necrotic factor-alpha against oxidative stress induced by graded exercise in sedentary men. Oxid Med Cell Longev. 2011; 2011:329643. PMC: 3163015. DOI: 10.1155/2011/329643. View

Hendershot C, Wardell J, Samokhvalov A, Rehm J . Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies. Addict Biol. 2016; 22(6):1515-1527. PMC: 6139429. DOI: 10.1111/adb.12425. View

SELZER M . The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Psychiatry. 1971; 127(12):1653-8. DOI: 10.1176/ajp.127.12.1653. View

Qrunfleh A, Alazizi A, Sari Y . Ceftriaxone, a beta-lactam antibiotic, attenuates relapse-like ethanol-drinking behavior in alcohol-preferring rats. J Psychopharmacol. 2013; 27(6):541-9. PMC: 3657312. DOI: 10.1177/0269881113482529. View

Shacham S . A shortened version of the Profile of Mood States. J Pers Assess. 1983; 47(3):305-6. DOI: 10.1207/s15327752jpa4703_14. View

Alhaddad H, Das S, Sari Y . Effects of ceftriaxone on ethanol intake: a possible role for xCT and GLT-1 isoforms modulation of glutamate levels in P rats. Psychopharmacology (Berl). 2014; 231(20):4049-57. PMC: 4176549. DOI: 10.1007/s00213-014-3545-y. View

Saunders J, Aasland O, Babor T, De la Fuente J, Grant M . Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993; 88(6):791-804. DOI: 10.1111/j.1360-0443.1993.tb02093.x. View

Mann K, Hoffmann S, Pawlak C . Does Acamprosate Really Produce its Anti-Relapse Effects via Calcium? No Support from the PREDICT Study in Human Alcoholics. Neuropsychopharmacology. 2016; 41(3):659-60. PMC: 4707814. DOI: 10.1038/npp.2015.175. View

Amen S, Piacentine L, Ahmad M, Li S, Mantsch J, Risinger R . Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. Neuropsychopharmacology. 2010; 36(4):871-8. PMC: 3052624. DOI: 10.1038/npp.2010.226. View

10.

Strickland J, Stoops W . Stimulus selectivity of drug purchase tasks: A preliminary study evaluating alcohol and cigarette demand. Exp Clin Psychopharmacol. 2017; 25(3):198-207. DOI: 10.1037/pha0000123. View

11.

Rao P, Saternos H, Goodwani S, Sari Y . Effects of ceftriaxone on GLT1 isoforms, xCT and associated signaling pathways in P rats exposed to ethanol. Psychopharmacology (Berl). 2015; 232(13):2333-42. PMC: 4465848. DOI: 10.1007/s00213-015-3868-3. View

12.

Rao P, Sari Y . Glutamate transporter 1: target for the treatment of alcohol dependence. Curr Med Chem. 2012; 19(30):5148-56. PMC: 3486951. DOI: 10.2174/092986712803530511. View

13.

OMalley S, Krishnan-Sarin S, Farren C, Sinha R, Kreek M . Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl). 2002; 160(1):19-29. DOI: 10.1007/s002130100919. View

14.

Litten R, Wilford B, Falk D, Ryan M, Fertig J . Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety. Subst Abus. 2016; 37(2):286-98. DOI: 10.1080/08897077.2015.1133472. View

15.

Davidson D, Camara P, Swift R . Behavioral effects and pharmacokinetics of low-dose intravenous alcohol in humans. Alcohol Clin Exp Res. 1997; 21(7):1294-9. View

16.

Fillmore M, Weafer J . Alcohol impairment of behavior in men and women. Addiction. 2004; 99(10):1237-46. DOI: 10.1111/j.1360-0443.2004.00805.x. View

17.

Martin C, Earleywine M, Musty R, Perrine M, Swift R . Development and validation of the Biphasic Alcohol Effects Scale. Alcohol Clin Exp Res. 1993; 17(1):140-6. DOI: 10.1111/j.1530-0277.1993.tb00739.x. View

18.

Siggins G, Martin G, Roberto M, Nie Z, Madamba S, De Lecea L . Glutamatergic transmission in opiate and alcohol dependence. Ann N Y Acad Sci. 2003; 1003:196-211. DOI: 10.1196/annals.1300.012. View

19.

Bujarski S, MacKillop J, Ray L . Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study. Exp Clin Psychopharmacol. 2012; 20(3):181-90. PMC: 3741097. DOI: 10.1037/a0027379. View

20.

Roberts-Wolfe D, Kalivas P . Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders. CNS Neurol Disord Drug Targets. 2015; 14(6):745-56. PMC: 4730383. DOI: 10.2174/1871527314666150529144655. View